Controversies and Challenges of Ventricular Assist Device Therapy

Evolving Mechanical Support Research Group (EMERG)

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Left ventricular assist device (LVAD) therapy has emerged as an increasingly vital facet of the treatment algorithm for advanced heart failure. Growing experience with LVAD support has led to substantial improvements in outcomes, with 1-year survival rates approaching that of cardiac transplantation. These therapeutic refinements have engendered growing interests in the potential for expanding the clinical indications for LVAD therapy to patients with less advanced heart failure. The primary obstacles to this evolution of care center largely on the prevention and/or management of the adverse events associated with LVAD therapy along with patient preference. Many programs also face the mounting difficulty of balancing quality outcomes with the increased volume of implants. During the recently assembled Users Meeting organized by St. Jude Medical, heart failure clinicians from nearly 50 LVAD implanting centers discussed these and other challenges and controversies impacting the field. The present review summarizes the key insights gleaned from this meeting.

Original languageEnglish (US)
Pages (from-to)1219-1224
Number of pages6
JournalAmerican Journal of Cardiology
Volume121
Issue number10
DOIs
StatePublished - May 15 2018

Fingerprint

Heart-Assist Devices
Heart Failure
Therapeutics
Patient Preference
Heart Transplantation
Survival Rate

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Evolving Mechanical Support Research Group (EMERG). / Controversies and Challenges of Ventricular Assist Device Therapy. In: American Journal of Cardiology. 2018 ; Vol. 121, No. 10. pp. 1219-1224.
@article{55ab372129fc441d8db259893a6830f4,
title = "Controversies and Challenges of Ventricular Assist Device Therapy",
abstract = "Left ventricular assist device (LVAD) therapy has emerged as an increasingly vital facet of the treatment algorithm for advanced heart failure. Growing experience with LVAD support has led to substantial improvements in outcomes, with 1-year survival rates approaching that of cardiac transplantation. These therapeutic refinements have engendered growing interests in the potential for expanding the clinical indications for LVAD therapy to patients with less advanced heart failure. The primary obstacles to this evolution of care center largely on the prevention and/or management of the adverse events associated with LVAD therapy along with patient preference. Many programs also face the mounting difficulty of balancing quality outcomes with the increased volume of implants. During the recently assembled Users Meeting organized by St. Jude Medical, heart failure clinicians from nearly 50 LVAD implanting centers discussed these and other challenges and controversies impacting the field. The present review summarizes the key insights gleaned from this meeting.",
author = "{Evolving Mechanical Support Research Group (EMERG)} and Brian Lima and Aditya Bansal and Jacob Abraham and Rich, {Jonathan D.} and Lee, {Sangjin S.} and Behzad Soleimani and Katz, {Jason N.} and Ahmet Kilic and Young, {John S.} and Patel, {Chetan B.} and Joseph, {Susan M.}",
year = "2018",
month = "5",
day = "15",
doi = "10.1016/j.amjcard.2018.01.034",
language = "English (US)",
volume = "121",
pages = "1219--1224",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10",

}

Evolving Mechanical Support Research Group (EMERG) 2018, 'Controversies and Challenges of Ventricular Assist Device Therapy', American Journal of Cardiology, vol. 121, no. 10, pp. 1219-1224. https://doi.org/10.1016/j.amjcard.2018.01.034

Controversies and Challenges of Ventricular Assist Device Therapy. / Evolving Mechanical Support Research Group (EMERG).

In: American Journal of Cardiology, Vol. 121, No. 10, 15.05.2018, p. 1219-1224.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Controversies and Challenges of Ventricular Assist Device Therapy

AU - Evolving Mechanical Support Research Group (EMERG)

AU - Lima, Brian

AU - Bansal, Aditya

AU - Abraham, Jacob

AU - Rich, Jonathan D.

AU - Lee, Sangjin S.

AU - Soleimani, Behzad

AU - Katz, Jason N.

AU - Kilic, Ahmet

AU - Young, John S.

AU - Patel, Chetan B.

AU - Joseph, Susan M.

PY - 2018/5/15

Y1 - 2018/5/15

N2 - Left ventricular assist device (LVAD) therapy has emerged as an increasingly vital facet of the treatment algorithm for advanced heart failure. Growing experience with LVAD support has led to substantial improvements in outcomes, with 1-year survival rates approaching that of cardiac transplantation. These therapeutic refinements have engendered growing interests in the potential for expanding the clinical indications for LVAD therapy to patients with less advanced heart failure. The primary obstacles to this evolution of care center largely on the prevention and/or management of the adverse events associated with LVAD therapy along with patient preference. Many programs also face the mounting difficulty of balancing quality outcomes with the increased volume of implants. During the recently assembled Users Meeting organized by St. Jude Medical, heart failure clinicians from nearly 50 LVAD implanting centers discussed these and other challenges and controversies impacting the field. The present review summarizes the key insights gleaned from this meeting.

AB - Left ventricular assist device (LVAD) therapy has emerged as an increasingly vital facet of the treatment algorithm for advanced heart failure. Growing experience with LVAD support has led to substantial improvements in outcomes, with 1-year survival rates approaching that of cardiac transplantation. These therapeutic refinements have engendered growing interests in the potential for expanding the clinical indications for LVAD therapy to patients with less advanced heart failure. The primary obstacles to this evolution of care center largely on the prevention and/or management of the adverse events associated with LVAD therapy along with patient preference. Many programs also face the mounting difficulty of balancing quality outcomes with the increased volume of implants. During the recently assembled Users Meeting organized by St. Jude Medical, heart failure clinicians from nearly 50 LVAD implanting centers discussed these and other challenges and controversies impacting the field. The present review summarizes the key insights gleaned from this meeting.

UR - http://www.scopus.com/inward/record.url?scp=85044286621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044286621&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2018.01.034

DO - 10.1016/j.amjcard.2018.01.034

M3 - Review article

C2 - 29576232

AN - SCOPUS:85044286621

VL - 121

SP - 1219

EP - 1224

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10

ER -